Comparative Pharmacology
Head-to-head clinical analysis: ELLENCE versus VALRUBICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELLENCE versus VALRUBICIN.
ELLENCE vs VALRUBICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Anthracycline topoisomerase II inhibitor and DNA intercalator, causing DNA damage and cell death.
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
Intravesical instillation: 800 mg (4 vials of 200 mg/5 mL) diluted in 25 mL of 0.9% Sodium Chloride Injection, instilled into the bladder once weekly for 6 weeks. Retain in bladder for 1-2 hours.
None Documented
None Documented
Clinical Note
moderateValrubicin + Digoxin
"Valrubicin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateValrubicin + Digitoxin
"Valrubicin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateValrubicin + Deslanoside
"Valrubicin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateValrubicin + Acetyldigitoxin
"Valrubicin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Terminal half-life is approximately 38 hours; clinically, it supports every-3-week dosing to avoid accumulation.
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
Primarily hepatic metabolism and biliary excretion; renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic